ArticleJournal of oncology2011
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood.
Article in Journal of oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 256 citations in OpenAlex.
- Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.Journal of translational medicine · 2018Trial
- Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.The pharmacogenomics journal · 2018Trial
- Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Trial
- Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.PloS one · 2013Trial
- Diagnostic efficacy of circulating tumor cell in clinically significant prostate cancer.Scientific reports · 2026Article
- Circulating tumor cell detection in cancer patients using in-flow deep learning holography.Npj biosensing · 2026Article
- Longitudinal CSF Tumor Cell Enumeration and Mutational Analysis as a Driver for Leptomeningeal Disease Management.Cancers · 2025Article
- EpCAM Signaling in Oral Cancer Stem Cells: Implications for Metastasis, Tumorigenicity, and Therapeutic Strategies.Current issues in molecular biology · 2025Review
- The integrated on-chip isolation and detection of circulating tumour cells.Sensors & diagnostics · 2024Review
- Method for Collecting Single Epithelial Cells from the Mouse Larynx.The Laryngoscope · 2024Article
- A FACS-based novel isolation technique identifies heterogeneous CTCs in oral squamous cell carcinoma.Frontiers in oncology · 2024Article
- The expansion of liquid biopsies to vascular care: an overview of existing principles, techniques and potential applications to vascular malformation diagnostics.Frontiers in genetics · 2024Review
- A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs.Journal of translational medicine · 2023Article
- mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.Molecular oncology · 2023Article
- Zwitterionic microgel preservation platform for circulating tumor cells in whole blood specimen.Nature communications · 2023Article
- The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Review
- Quantification of capture efficiency, purity, and single-cell isolation in the recovery of circulating melanoma cells from peripheral blood by dielectrophoresis.Lab on a chip · 2023Article
- Aptamers Targeting Membrane Proteins for Sensor and Diagnostic Applications.Molecules (Basel, Switzerland) · 2023Review
- Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients.Biosensors & bioelectronics · 2023Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enrichment of rare circulating tumor cells (CTCs) in blood is typically achieved using antibodies to epithelial cell adhesion molecule (EpCAM), with detection using cytokeratin (CK) antibodies. However, EpCAM and CK are not expressed in some tumors and can be downregulated during epithelial-to-mesenchymal transition. A micro-fluidic system, not limited to EpCAM or CK, was developed to use multiple antibodies for capture followed by detection using CEE-Enhanced (CE), a novel in situ staining method that fluorescently labels the capture antibodies bound to CTCs. Higher recovery of CTCs was demonstrated using antibody mixtures compared to anti-EpCAM. In addition, CK-positive breast cancer cells were found in 15 of 24 samples (63%; range 1-60 CTCs), while all samples contained additional CE-positive cells (range 1-41; median = 11; P = .02). Thus, antibody mixtures against a range of cell surface antigens enables capture of more CTCs than anti-EpCAM alone and CE staining enables the detection of CK-negative CTCs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.